Century Therapeutics, Inc.

Century Therapeutics, Inc. entered into an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., its Chief Scientific Officer. Under the new agreement, Dr. Cowan will continue in his role on a part-time basis. His annual salary will be reduced to $296,150, and he will be eligible for a pro-rated annual performance-based target bonus.

Century Therapeutics, Inc. announced that its stockholders approved an amendment to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 at its Annual Meeting held on June 11, 2026. This amendment became effective on June 12, 2026. Additionally, Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. were elected as Class II directors, and Ernst & Young LLP was ratified as the independent auditor for the 2026 fiscal year.

Century Therapeutics, Inc. announced the presentation of preclinical data for its investigational iPSC-derived islet replacement therapy, CNTY-813, at the American Diabetes Association (ADA) 2026 Scientific Sessions. The data highlighted durable glucose control, immune evasion capabilities of its Allo-Evasion™ 5.0 technology, and a successfully established Phase 1 clinical manufacturing process. The company remains on track for an IND submission in Q4 2026, with initial clinical data anticipated in 2H 2027, positioning CNTY-813 as a potential functional cure for Type 1 Diabetes.

Century Therapeutics announced positive new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, at the American Diabetes Association 86th Scientific Sessions. The data showed durable glucose control for over eight months in preclinical models and confirmed the efficacy of its Allo-Evasion™ 5.0 technology in maintaining normoglycemia without immunosuppression. The company has also established its Phase 1 clinical manufacturing process and remains on track for an IND submission in 4Q 2026, with initial clinical data expected in 2H 2027.

Century Therapeutics reported a net loss of $21.6 million for Q1 2026, a significant decrease from a net income of $76.6 million in Q1 2025, primarily due to no collaboration revenue this quarter. Despite the financial loss, the company highlighted strong pipeline execution, with its lead type 1 diabetes program, CNTY-813, on track for an IND submission in Q4 2026 and initial clinical data in H2 2027. Century also plans to advance CNTY-308 into clinical testing in 2026 and maintains a cash runway into Q1 2029, supported by a recent $135 million private placement.

Century Therapeutics reported a net loss of $(21.6) million for the three months ended March 31, 2026, a significant decline from a net income of $76.6 million in the prior-year period, primarily due to zero collaboration revenue compared to $109.2 million in Q1 2025. The company also saw a decrease in R&D and G&A expenses. Despite the loss, the company raised $126.4 million from a PIPE offering, strengthening its financial position with total stockholders' equity increasing to $264.7 million.

Century Therapeutics reported Q1 2026 financial results and provided key business highlights. The company's lead program, CNTY-813 for type 1 diabetes, remains on track for IND submission in 4Q 2026, with initial clinical data expected in 2H 2027. Additionally, CNTY-308 is set to advance into clinical testing this year. Century Therapeutics maintains a strong financial position with $217.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a cash runway into 1Q 2029. The company reported a net loss of $21.6 million for the quarter.

Century Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Key proposals include the election of two Class II directors and the ratification of Ernst & Young LLP as the independent auditor. The company also seeks approval to increase its authorized common stock from 300 million to 450 million shares. Additionally, the filing highlighted recent corporate progress, including a $135 million investment and advancements in its clinical programs.